Prostate cancer treated by anti-androgens: is sexual function preserved? by Schröder, F H et al.
The data presented in this report describe the results of the first
evaluation of sexual potency obtained within a prospective, open,
randomized study of previously untreated patients with metastatic
prostate cancer (EORTC protocol 30892). Cyproterone acetate
(CPA) as standard treatment and with a well established castration-
like effect on libido and potency (Ahrens, 1990) is compared with
flutamide (FLU), which is considered to preserve libido and
potency (Sogani et al, 1984; Lund and Rasmussen, 1988; Boccon-
Gibod, 1998). The European Organization for Research and
Treatment of Cancer (EORTC) study 30892 was set up to compare
the effectiveness of monotherapy with flutamide versus CPA in
men with metastatic prostate cancer with favourable prognostic
factors. An additional goal was to explore the possibility of
utilizing less aggressive (minimally invasive?) endocrine treat-
ment of prostate cancer patients, which would improve quality of
life under treatment for those who are potent and sexually active
and wish to remain so. The main end points of this study, which
have not yet been reached and which are not subject to this report,
are time to progression, cancer-specific and overall survival. The
‘soft approach’ of anti-androgen monotherapy was chosen on the
background of negative findings of the EORTC Genitourinary
(GU) Group with relation to the use of maximal androgen
blockade (MAB) (Robinson et al, 1995; Voogt et al, 1998).
Marginal, but no significant benefit of MAB has recently been
shown by a metaanalysis and no benefit was seen in a large
American study (Dalesio et al, 1995; Eisenberger et al, 1998).
MATERIALS AND METHODS
Evaluation of potency
Evaluation of potency and sexual activity was carried out at entry,
at 3-monthly visits during the first 2 years of treatment and 6-
monthly thereafter until progression, by means of a physician-
administered questionnaire. Five questions were asked. The
questions were supplied in English to all participating centres,
which were located in the UK, The Netherlands, Italy, Belgium,
Turkey and six other European countries. The questions had to be
translated ad hoc by the treating physician and asked in the
patients’ mother tongue. The English phrasing of the questions
was as follows:
Prostate cancer treated by anti-androgens: is sexual
function preserved?
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Summary This paper reports on results of the EORTC protocol 30892, an open, prospective, randomized study of 310 patients with
previously untreated metastatic prostate cancer with favourable prognostic factors who were treated by either flutamide (FLU) or cyproterone
acetate (CPA) monotherapy. The final analysis with regard to the main end points, time to progression and survival are still pending. Final
results related to the evaluation of sexual functioning prior to and under treatment are reported here. Of 310 randomized patients 294 were
eligible for evaluation within this side study. The median age was 71 years (range 48–85). Potential risk factors related to age, general health
and prostate cancer were evaluated. For evaluation of sexual functions a five-item questionnaire was used which was administered by the
investigator. The protocol allowed time dependent observations at 3-monthly follow-up visits. Sexual functioning was dependent on age but
not on prostate cancer-related parameters. Sexual functions at entry were similar within the two treatment groups, spontaneous (nightly)
erections and sexual activity were seen in 43–51% and 29–35% of cases. Under treatment, sexual functions under FLU and CPA declined
slowly with median times of 12.9 and 5.8 months versus 13.7 and 8.9 months respectively for spontaneous erections and sexual activity.
Eventually, with an average observation time in excess of 2 years, loss of spontaneous erections and of sexual activity occurred in 80%
versus 92% and in 78% versus 88% of men under FLU versus CPA treatment respectively. None of these differences reached statistical
significance. Maintenance of potency under treatment with FLU as reported in the literature is not confirmed in this study. However, loss of
sexual functions under monotherapy with both antiandrogens is slow and 10–20% of men retain sexual activity after 2–6 years of treatment.
This observation can be exploited in new treatment schemes and is likely to lead to improved quality of life. The advantage of FLU in time and
total preservation of sexual functions is statistically not significant and must be balanced against the side effects of FLU and other pure
antiandrogens, which may exceed those of CPA especially with respect to gynaecomastia. Hepatic toxicity may limit the long-term use of both
drugs. © 2000 Cancer Research Campaign
Keywords: prostate cancer; anti-androgens; sexual function
283
British Journal of Cancer (2000) 82(2), 283–290
© 2000 Cancer Research Campaign
Article no. bjoc.1999.0916
Received 5 March 1999
Revised 29 July 1999
Accepted 5 August 1999
Correspondence to: FH Schröder
*Major contributors: M Pavone-Macaluso, Palermo; J Mattelaer, Kortrijk; RPF van
Velthoven, Brussels; DWW Newling, Amsterdam; UE Studer, Bern; M Brausi,
Carpi; A Akdas, Istanbul; L Denis, Antwerp; M de Pauw, Brussels1. Did you notice an erect penis sometimes during the night or
when waking up in the last 3 months?
2. Do you consider yourself sexually active in some way?
3. Do you have an erection with sexual excitement?
4. Do you reach an orgasm during sexual activity?
5. Do you ejaculate with sexual activity?
Questions 3, 4 and 5 were only to be asked if question 2 was
answered with ‘yes’. Throughout this paper the term ‘potent’ is
applied for men who answered ‘yes’ to questions 2 and/or 1.
The questions
This protocol was designed during 1988. The questions were
selected and modified from questionnaires proposed by Frenken
(1978). These questionnaires were the most advanced source vali-
dated instruments available at that time. The translations and the
combination of the simplified list of five questions used in this
protocol were not validated.
In selecting the questions it was considered that older men often
do not have a partner. They may be sexually active in some way
without actually having intercourse. It seemed to be in the interest
of the accuracy of the evaluation to include such situations. For
this reason, the obvious question: ‘Are you able to have sexual
intercourse?’ was not included. The basic thought was that organic
functioning and libido could best be assessed by questions 1 and 2.
This included the possibility that a man might be sexually active
without actually having erections. For this reason, for those men
who answered question 2 with yes, further specification is
requested in questions 3, 4 and 5.
Definitions
The following eligibility rules for evaluation were established:
• Patients who answered ‘yes’ to question 1 and/or 2 (for
potency at entry) and who had at least one follow-up form
available were included in the evaluation of potency at entry
and in the time-dependent analysis.
• Recovery of potency: Some patients answered ‘no’ on question
1 and/or 2 at entry, but ‘recovered’ potency later on. They
were considered to be potent at entry and were included in the
time-dependent analysis.
• Time to definite disability: Time to definite disability of a
given function is defined as the time from entry on study to the
date of definitive loss of the function, which is defined as the
date of the first reported ‘no’, which is not followed by a ‘yes’
to the given question at any subsequent follow-up visit. The
time to definitive disability of each function has been analysed
as a time to event function using Kaplan–Meier curves.
• Transient disability of the function is defined as any ‘no’
reported by the patient, irrespective of his answers to the ques-
tion at subsequent follow-up visits. Thus, the expression ‘tran-
sient loss’ includes those men who lost a given function
definitively or temporarily. The frequency of definitive loss of
functions and the frequency of transient loss with inclusion of
transient loss are separately calculated for the two treatment
arms.
Statistics
The original sample size calculation of protocol 30892 was based
on time to progression, cancer specific survival and overall
survival, a sample size calculation related to the potency outcome
was not done.
Percentages were compared by the use of the c2 test (*)
(Agresti, 1990) or the c2 test for linear trend (**) (Armitage, 1995)
whenever the variables had more than two ordered categories.
Standard Kaplan–Meier curves were used to estimate the time to
the loss of sexual functions (Kaplan and Meier, 1958). These were
compared using the log-rank test (***) (Mantel, 1966). All tests
were two-sided and the 0.05 significance level was used.
RESULTS
The overall rate of sexual potency was rather low. A total of 138 of
294 men (47%) claimed to have morning erections at entry and
only 94/294 (32%) were sexually active.
Eligibility
Of the 310 patients, 294 were eligible for the evaluation of potency
at entry into the study. Two-hundred and seventy-eight men with
follow-up information regarding potency are eligible to the evalu-
ation of loss of sexual functions and of their time-dependent 
evaluation. The lack of follow-up of a total of 33 men was due to
incomplete patient cooperation as well as other factors.
Baseline characteristics
Baseline characteristics of patients were evaluated with respect to
morning/night erections (question 1) and sexual activity (question
2) at entry. These characteristics included: age, performance
status, chronic associated disease, previous prostate surgery and
other treatment, the TNM categories and the grade of differentia-
tion. An attempt was made to identify characteristics as possible
risk factors for the loss of sexual functions. As one would expect,
the proportion of men who have nightly or morning erections and
who are sexually active decreases with age (P = 0.001). A
decreased WHO performance status seems to have a similar
impact though the effect does not reach statistical significance. All
characteristics did not have any impact (original data not shown).
The baseline patient characteristics were also compared
between the treatment arms. It appeared that the patients entered
on the CPA arm were significantly younger than those on the FLU
arm (P = 0.003) with a median age of 69 years (range 51–85) as
compared to 73 years (range 48–85) on the FLU arm. This needs
to be taken into account when comparing potency between the two
treatment arms since age is a strong predicting factor for potency.
At the time of this evaluation only 62 of the 278 eligible patients
were still on study and under treatment. Of these, 28 were sexually
active at base-line and those contribute to the analysis of potency.
Eight of these 28 were still sexually active in some way at the time
of their last follow-up visit. The only additional information that
could be obtained would be an update on these eight patients, who
might or might not lose their potency. One may expect that this
will not change any of the figures used in the comparisons. Further
follow-up on these eight men would not change the final conclu-
sions of the paper. For these reasons this evaluation is considered
definite.
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Potency at entry is assumed if questions 1 and/or 2 were answered
positively initially or if positive answers were obtained during the
course of treatment after initial denial. Table 1 indicates potency at
entry or recovery of functions under treatment by FLU or CPA
according to our definitions. It can be seen that the distribution of
sexual functioning in the different categories between the two
treatment arms is rather similar at entry, no statistically significant
differences are encountered. As already mentioned questions 3–5
were asked only if question 2 was answered positively. The results
can therefore be read as follows: in, for example the FLU group,
43 patients were considered to be sexually active, of these 42 expe-
rienced erections with sexual excitement, 41 were able to reach an
orgasm and 38 ejaculated. The small differences seen in totals
between the treatment groups are not statistically significant. More
patients recovered under treatment with CPA than with FLU.
Again, the numbers do not reach statistical significance. Some of
these patients recovered late after their entry on study, though for
the majority the recovery occurred within 1 year of entry on study.
Including these patients in the time-dependent evaluation of
potency may slightly bias the results towards a decrease of the
difference between FLU and CPA. Also, the fact that the patients
were slightly younger on CPA is likely to bias the comparison in
the same way. The analysis was repeated including only those who
were ‘potent’ at entry (and with exclusion of those who recovered
‘potency’), and also with a stratification for age. The conclusions
did not change, no statistical significance was encountered.
Time-dependent evaluation
Table 2 indicates the proportion of those who lost one of five
sexual functions under study during the follow-up under treatment.
Definite and transient loss of functions are defined in the methods
sections.
The totals of those of whom sexual functions are reported in
Table 1 are taken over as reference values in Table 2 after
excluding those men who did not have at least one follow-up form
available. This correction explains the small differences in the total
number of patients considered for each question as compared to
Table 1. This situation occurred only in the FLU arm.
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Table 1 Potency at entry or recovery under treatment (if not functioning at entry)
FLU CPA P-value
n = 147 n = 147
N (%) N (%)
1. Morning erections 54 (36.7) 61 (41.5) 0.409
Recovery 9 (6.1) 14 (9.5) 0.386
Totala 63 (42.9) 75 (51.0) 0.161
2. Sexually active 38 (25.9) 40 (27.2) 0.579
Recovery 5 (3.4) 11 (7.5) 0.123
Totala 43 (29.3) 51 (34.7) 0.317
3. Erections with sexual excitement 36 (24.5) 37 (25.2) 0.893
Recovery 6 (4.1) 10 (6.8) 0.304
Totala 42 (28.6) 47 (32.0) 0.794
4. Orgasm present 37 (25.2) 38 (25.9) 0.894
Recovery 4 (2.7) 8 (5.4) 0.238
Totala 41 (27.9) 46 (31.3) 0.523
5. Ejaculation present 34 (23.1) 34 (23.1) 0.999
Recovery 4 (2.7) 5 (3.4) 0.735
Totala 38 (25.9) 39 (26.5) 0.447
aThese patients are included in the time course evaluation per treatment but only if at least one follow-up form was available.
Table 2 Definite and transient loss of potency in men functioning at entry or with recovery of function under treatment per
treatment regimen
FLU CPA P-value
n = 136 n = 142
n (%) n (%)
1. Morning erections Definitive loss 43/60 (71.7) 5910/75 (78.7) 0.347
Transient loss 48/60 (80.0) 69/75 (92.0) 0.042
2. Sexually active Definitive loss 31/41 (75.6) 36/51 (70.6) 0.590
Transient loss 32/41 (78.1) 45/51 (88.2) 0.189
3. Erections with Definitive loss 35/40 (87.5) 36/47 (76.6) 0.191
sexual excitement Transient loss 36/40 (90.0) 41/47 (87.2) 0.687
4. Orgasms Definitive loss 33/39 (84.6) 36/46 (78.3) 0.455
Transient loss 34/39 (87.2) 44/46 (95.6) 0.157
5. Ejaculation Definitive loss 32/36 (88.9) 32/39 (82.1) 0.586
Transient loss 32/36 (88.9) 38/39 (97.4) 0.138
Questions 3–5 only to be asked if the answer to question 1 was ‘yes’. Only men with at least one follow-up form are included.The set up of the study allows to evaluate sexual functions in a
time-dependent fashion. At the time of this evaluation the median
follow-up amounts to 3.3 years for potency and to 4.5 years for the
survival status. The difference in duration of follow-up relates to
the evaluation of the potency status being stopped whenever the
patients stop the protocol treatment.
The following observations are made: in the FLU group fewer
patients lost morning erections and sexual activity than in the CPA
group. The difference with respect to morning erections is statisti-
cally significant (P = 0.042). Significance is not reached for the
difference in loss of sexual activity (78.1 vs 88.2%). Small differ-
ences with regard to questions 3, 4 and 5 again turn out not to be
statistically significant. It is remarkable that with prolonged treat-
ment morning erections and sexual activity are preserved under
FLU in 20.0 and 21.9% and also with CPA in 8 and 11.8%
respectively. The same analysis on only the patients who are posi-
tive at entry, excluding those who recovered under treatment gave
similar results.
In Table 3 the time to the definitive loss of sexual functions is
summarized per treatment group. Again, there are no significant
differences. However, there seems to be a trend towards a longer
preservation of morning erections and sexual activity in men who
use FLU. The median times to loss of morning erections and
sexual activity amount to 12.9 months and 13.7 months under FLU
and to 5.8 and 8.9 months under CPA. These differences, however,
are not significant, probably because of small numbers and wide
confidence intervals. Median times in this context indicate the
time until 50% of all men have lost the respective function. Loss of
ejaculation is reported much earlier than the loss of all other func-
tions under study.
When the analyses were repeated with exclusion of patients
who answered negatively at baseline and recovered under treat-
ment the same conclusions were reached. Because the observed
difference in the distribution of the age of the patients between the
two groups may introduce a bias in the comparisons, analyses
stratified for age were also carried out, again leading to similar
conclusions.
A consort diagram (Figure 1) indicates the flow of events
related to question 2 (sexually activity) per treatment arm.
Figure 2A–D further illustrates these findings. The most impor-
tant observation may be that loss of sexual functions rarely occurs
abruptly, but in most patients within a year from start of treatment.
There is a trend toward a more favourable time course under FLU
treatment than under CPA. Also, it is interesting that some patients
retain their sexual functions for long time periods lasting between
2 and 6 years. Most projections level off between 10 and 20%.
None of the Kaplan–Meier projections, which indicate the time
course of change for each question reveal a statistically significant
advantage of one of the treatment group above the other. Adjusting
the analysis for the influence of progressive disease did not change
the conclusions.
DISCUSSION
At the time this study was set up (1988), a literature review did not
reveal any measuring instrument for sexual potency that was
specifically designed for the intended study. The questionnaire
from which most of the questions were adapted (Frenken, 1978)
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Randomization (n = 310)
Eligible (294)
Questions FLU (147) CPA (147)
n (%) n (%)
Sexually active at entry 38 (25.8) 40 (27.2)
Recovery 5   (3.4) 11 (7.5)
Total active 41 (27.9) 51 (34.7)
Transient loss (only applicable
if potent at entry) 32 (78.1)* 45 (88.2)*
Definite loss under treatment 31 (75.6)* 36 (70.6)*
Median time to loss (months) 13.7 8.9
* % of all active at entry.
Figure 1 Consort diagram relating to sexual activity (Question 2) at entry
and during/after treatment by cyproterone acetate or flutamide
Table 3 Time to definitive loss of sexual functions per treatment arm (all patients with activity at baseline or recovery)
Observed Median (95% Cl) P-value
diagnosis/ (months)
total numbers
1. Morning erections
FLU 43/60 12.9 9.9–23.4
CPA 59/75 5.8 3.5–12.6 = 0.154
2. Sexually active
FLU 31/41 13.7 8.8–21.4
CPA 36/51 8.9 3.6–17.0 = 0.907
3. Erections with
sexual excitement
FLU 35/40 10.0 3.6–15.8
CPA 36/47 5.8 2.4–16.5 = 0.684
4. Orgasm
FLU 33/39 8.8 3.6–15.8
CPA 36/46 8.3 2.5–16.5 = 0.616
5. Ejaculation
FLU 32/36 4.0 2.7–15.8
CPA 33/39 3.1 1.8–8.9 = 0.924was at that time validated within The Netherlands and for popula-
tion-based but not disease-related studies. At the time of the design
of this protocol the EORTC-GU group had to settle for a strongly
simplified and still effective set of questions, which could be
adapted to a multicentre setting, the involvement of multiple
nationalities, the need for providing one protocol in the English
language and the logistic difficulty of providing validated transla-
tions of the questionnaire in the 11 languages of the countries
involved in this protocol, which would have been necessary if a
patient administered questionnaire had been considered. The
purpose was to design questions that would measure organic
sexual function (question 1), libido combined with sexual capabil-
ities (question 2) and sexual satisfaction (questions 3, 4 and 5) of
those who were sexually active. Only in recent years more elabo-
rate measuring instruments have been developed (Feldman et al,
1994; Fitzpatrick et al, 1998) such as the nine-item questionnaire
used in the Massachusetts Male Aging Study (MMAS), and within
a Swedish study comparing general age matched population to
prostate cancer cases untreated and under various forms of treat-
ment (Helgason et al, 1998). Obviously, these efforts to develop
measuring instruments have all led to different questionnaires and
different methodology of evaluation so that literature-based
comparisons are very difficult.
Potency at entry
Within this report, males who claim to have spontaneous erections
at night or in the morning and/or those who claim to be sexually
active in some way, are considered to be potent. The presence of
spontaneous erections is often but not always associated with the
desire of being sexually active. Potency at entry into the study
(spontaneous erections or sexual activity) was reported in 138/294
(46.9%). Ninety-four out of 294 (32.0%) men included those who
scored negative for these questions initially but regained sexual
functions during the course of treatment. The study does not
provide a control group that would allow judgement on the impact
of prostate cancer with respect to sexual functioning of men of a
similar age without prostate cancer. In agreement with the MMAS
(Feldman et al, 1994) and the data provided by Helgason et al
(1998) this study showed that potency is strongly age-related. The
MMAS study differentiates between minimal, moderate and
complete loss of potency. A total of 1290 of 1707 men aged 40–70
provided answers to a self administered nine-item questionnaire. A
comparison with the data obtained in the present study is impos-
sible. However, even considering a very much younger average
age, the combined prevalence of minimal, moderate and complete
impotence was 52%. Among men aged 65–70 years the combined
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Figure 2 Kaplan–Meier projections of time to loss of sexual functions (Questions 1–4). Patients recovering functions during treatment are indicated. 
(A) morning/night erections, P = 0.154; (B) sexual activity, P = 0.907; (C) erections with sexual excitement, P = 0.684; (D) orgasm, P = 0.616rate of moderate and complete impotence was about 53%. The
Swedish study (Helgason et al, 1998) reports on ‘any decrease of
sexual function’ with time in 342 men with untreated prostate
cancer compared to an age-matched cohort of 314 men without
prostate cancer. Loss of sexual desire, erectile function and orgasm
was reported by 51, 77 and 71% in men without prostate cancer
and by 75, 90 and 83% in men with prostate cancer. Morley (1988)
found a rate of impotence of 27% in men more than 50 years old
undergoing a general health screening. Diokno et al (1990)
reported 40% impotence in 283 men who were older than 60 years.
Many of the participants were aware of the diagnosis of prostate
cancer prior to entry into this protocol for various periods of time.
This may explain why some men had lost all sexual interest and
felt that they might have become impotent at entry. With the usual
remission of the disease under endocrine treatment and due to
other accompanying circumstances such as a new partner, sexual
interest and potency have returned in some as indicated in Tables 1
and 2.
Time-dependent observations
Loss of potency under treatment with anti-androgens, pure (FLU)
or steroidal (CPA) is a slow process. Median times to loss of
sexual functions, as indicated in Table 3, vary between 5.8 and
12.9 months for morning erections and between 8.9 and 13.7
months for sexual activity between the CPA and FLU arms,
respectively. The outcome with relation to almost all functions is
more favourable as far as the time to their loss is concerned within
the FLU-treated group of patients. However, these differences do
not reach statistical significance. In this respect the study is incon-
clusive. The study, however, does not confirm previous studies
with reported persistence of potency under treatment with FLU
(Sogani et al, 1984; Lund and Rasmussen, 1988; Boccon-Gibod,
1998). The observation that some men remain potent under
endocrine treatment is not new. Ellis and Grayhack (1963)
reported that after castration, treatment with oestrogens or the
combination of both 16 of 38 previously potent men remained
potent over a prolonged period of time. The mechanism of main-
tained potency and sexual activity after castration as well as the
mechanism of loss of potency clearly is not completely under-
stood.
The investigators considered the fact that sexual partners are not
involved in this protocol as one of the weaknesses of this study.
For this reason, from time to time, partners who attended
consultations were interviewed together with the patients. The
sexual abilities and activity of the couple were confirmed by the
partner on many occasions at the senior author’s institution.
In spite of this rather disappointing result, the use of what might
be called ‘minimally invasive endocrine treatment’ with preserva-
tion of potency and a step-up scheme to more aggressive treatment
once progression occurs, seems a realistic option based on the
observation that half of the previously sexually active patients
remain active for a year under FLU treatment and almost 9 months
under treatment with CPA. This applies only if equal effectiveness
with castration or an LHRH agonist could be proven in a prospec-
tive randomized study. Goldenberg et al (1995) have proposed
intermittent endocrine treatment, a regimen that allows treatment-
free periods of 4–6 months after similar periods of endocrine treat-
ment. Intermittent endocrine treatment is at present subject to
several large phase III studies. Because of the reversibility of the
effect of anti-androgens and, especially utilizing the observation
that the onset of impotence is a slow process under this type of
treatment, pure anti-androgens and also steroidal anti-androgens
may be ideal agents for use in intermittent treatment regimens of
endocrine therapy. They might provide a 50% or more chance that
men remain potent even during the active treatment. The occur-
rence of gynaecomastia in more than 40% of cases with the use of
a pure anti-androgen is a problem that needs to be considered
when taking these decisions (Schröder et al, 1997). Painful gynae-
comastia was seen in 59–130 patients treated by FLU (45.4%) and
in 10/134 patients treated with CPA (7.5%) P = < 0.001. Two
patients in the FLU arm elected to discontinue treatment because
of gynaecomastia. A correlation between gynaecomastia and loss
of sexual functions was not seen. Another antiandrogen, which is
available for clinical use in most countries, Bicalutamide®, may
have a more favourable side-effect profile. However, the preva-
lence of gynaecomastia seems to be similar to FLU (Blackledge,
1996).
The problem of maintaining potency under endocrine treatment
will become more relevant in the future, because prostate cancer is
increasingly diagnosed at an earlier age. The diagnosis is more
frequently based on an elevation of serum prostate-specific
antigen (PSA) which has been shown to produce a lead time (the
time diagnosis is moved forward with relation to the time of
clinical diagnosis) of 6–10 years (Stenman et al, 1994). While the
average age in this patient population amounts to 71 years the
average age of men in populations diagnosed by the use of PSA
driven diagnostics is clearly below 60. In addition, at this time
adjuvant endocrine treatment and the issue of early versus delayed
endocrine treatment of prostate cancer are still not fully under-
stood (The Medical Research Council Prostate Cancer Working
Party Investigators Group, 1997). Whatever developments in the
near future will show: the age of men who are diagnosed to have
prostate cancer will decrease and the relevance of the problem of
sexual functioning will increase. With the recognition that
maximal anti-androgen blockade has only minimal or no added
value at all, and the expected prolonged periods of endocrine treat-
ment with earlier diagnosis, it is necessary to investigate alterna-
tive treatment schemes. In spite of the observation that
potency-related sexual functions decrease with time under anti-
androgens, the observations presented in this paper give an
opening for the development of new endocrine treatment strategies
which take into consideration the quality of life related to sexual
functioning.
Relevant background information
Head on randomized comparison has not shown superiority of
diethylstilboestrol (Pavone-Macaluso et al, 1986) and ethiny-
loestradiol (Jacobi et al, 1980) to CPA. Conclusive information on
FLU monotherapy in comparison with standard treatment is not
available, smaller trials show no difference with respect to time to
progression and survival (Lund and Rasmussen, 1988; Boccon-
Gibod, 1998).
CONCLUSIONS
In this study of 294 men with metastatic prostate cancer and
favourable prognostic factors sexual function was studied over
time. A simple, five-item questionnaire was used. In comparing
the pure anti-androgen FLU to the steroidal anti-androgen CPA
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might be entirely preserved in the FLU arm was not confirmed.
However, the paper allows a number of important conclusions.
The initial rate of sexual dysfunction was rather high, probably
higher than in the age-matched general population. The diagnosis
of prostate cancer seems to have considerable impact on libido and
sexual functioning in itself. This concept is supported by the fact
that some men under both treatment regimens recovered sexual
functions under treatment which were not reported at entry. In
general, sexual function under FLU treatment was preserved in a
higher proportion of men and for longer periods of time than under
CPA. These differences, however, did not reach statistical signifi-
cance. The observation that loss of potency under these treatment
regimens is slow, may still give an opening for the improvement of
sexuality-related quality of life in men with prostate cancer under
endocrine treatment if the observations of this study are applied to
new, ingenious treatment regimens.
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